Pennington Biomedical Research Center, 6400 Perkins Road, Baton Rouge, LA 70808, USA.
Curr Hypertens Rep. 2013 Jun;15(3):182-9. doi: 10.1007/s11906-013-0343-6.
After a long period of failure in development, two new medications (phentermine/topiramate ER - Qsymia™ and lorcaserin - Belviq®) have been approved by the US Food and Drug Administration for long-term weight management in persons with obesity (BMI ≥ 30 kg/m(2)) or in overweight persons (BMI ≥ 27 kg/m(2)) with comorbidities. Another medication, bupropion/naltrexone, is undertaking a cardiovascular outcomes trial and an analysis in 2014 will determine its approval and release. The most widely prescribed drug for obesity, phentermine, used since 1959 for short-term weight management, has been released in a new formulation. This paper reviews these new medications, and other important events in the landscape for management of obesity, with an eye to the interests of physicians who manage hypertension. All the new drugs under discussion are re-fittings of old agents or fresh approaches to old targets; thus, what is old is new again in the pharmacotherapy of obesity.
经过长期的研发失败，两种新的药物（安非他酮/纳曲酮缓释片和lorcaserin - Belviq®）已被美国食品和药物管理局批准用于肥胖症患者（BMI≥30kg/m²）或超重患者（BMI≥27kg/m²）的长期体重管理，这些患者伴有合并症。另一种药物，安非他酮/纳曲酮，正在进行心血管结局试验，2014 年的一项分析将决定其批准和发布。最广泛用于肥胖症的药物安非他酮，自 1959 年以来用于短期体重管理，现已推出新的配方。本文回顾了这些新药物以及肥胖症管理领域的其他重要事件，着眼于管理高血压的医生的利益。正在讨论的所有新药都是旧药物的重新配制或针对旧靶点的新方法；因此，肥胖症药物治疗中的旧药又有了新用途。
